MétaCan
Menu
Back to cohort
Record W2938027205 · doi:10.1136/bmjopen-2018-024908

Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients

2019· article· en· W2938027205 on OpenAlexafffundabout
Julie Ho, Atul Sharma, Kristine Kroeker, Robert Carroll, Sacha De Serres, Ian W. Gibson, Patricia Hirt‐Minkowski, Anthony M. Jevnikar, See Kim, Greg Knoll, David N. Rush, Chris Wiebe, Peter Nickerson

Bibliographic record

VenueBMJ Open · 2019
Typearticle
Languageen
FieldMedicine
TopicRenal Transplantation Outcomes and Treatments
Canadian institutionsUniversity of OttawaGeorge & Fay Yee Centre for Healthcare InnovationUniversity of TorontoUniversité LavalWestern UniversityUniversity of Manitoba
FundersInstitute of Nutrition, Metabolism and DiabetesCanadian Institutes of Health ResearchFonds de Recherche du Québec - SantéUniversity of Manitoba
KeywordsMedicineSubclinical infectionTransplantationKidney transplantationBiopsyInternal medicineRandomized controlled trialUrineUrologySurgery

Abstract

fetched live from OpenAlex

INTRODUCTION: Subclinical inflammation is an important predictor of death-censored graft loss, and its treatment has been shown to improve graft outcomes. Urine CXCL10 outperforms standard post-transplant surveillance in observational studies, by detecting subclinical rejection and early clinical rejection before graft functional decline in kidney transplant recipients. METHODS AND ANALYSIS: This is a phase ii/iii multicentre, international randomised controlled parallel group trial to determine if the early treatment of rejection, as detected by urine CXCL10, will improve kidney allograft outcomes. Incident adult kidney transplant patients (n~420) will be enrolled to undergo routine urine CXCL10 monitoring postkidney transplant. Patients at high risk of rejection, defined as confirmed elevated urine CXCL10 level, will be randomised 1:1 stratified by centre (n=250). The intervention arm (n=125) will undergo a study biopsy to check for subclinical rejection and biopsy-proven rejection will be treated per protocol. The control arm (n=125) will undergo routine post-transplant monitoring. The primary outcome at 12 months is a composite of death-censored graft loss, clinical biopsy-proven acute rejection, de novo donor-specific antibody, inflammation in areas of interstitial fibrosis and tubular atrophy (Banff i-IFTA, chronic active T-cell mediated rejection) and subclinical tubulitis on 12-month surveillance biopsy. The secondary outcomes include decline of graft function, microvascular inflammation at 12 months, development of IFTA at 12 months, days from transplantation to clinical biopsy-proven rejection, albuminuria, EuroQol five-dimension five-level instrument, cost-effectiveness analysis of the urine CXCL10 monitoring strategy and the urine CXCL10 kinetics in response to rejection therapy. ETHICS AND DISSEMINATION: The study has been approved by the University of Manitoba Health Research Ethics Board (HS20861, B2017:076) and the local research ethics boards of participating centres. Recruitment commenced in March 2018 and results are expected to be published in 2023. De-identified data may be shared with other researchers according to international guidelines (International Committee of Medical Journal Editors [ICJME]). TRIAL REGISTRATION NUMBER: NCT03206801; Pre-results.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.030
metaresearch head score (Gemma)0.032
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.059
Threshold uncertainty score0.199

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0300.032
Meta-epidemiology (narrow)0.0070.002
Meta-epidemiology (broad)0.0120.004
Bibliometrics0.0010.002
Science and technology studies0.0020.003
Scholarly communication0.0030.003
Open science0.0030.002
Research integrity0.0080.007
Insufficient payload (model declined to judge)0.0590.009

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.066
GPT teacher head0.417
Teacher spread0.351 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations23
Published2019
Admission routes3
Has abstractyes

Explore more

Same venueBMJ OpenSame topicRenal Transplantation Outcomes and TreatmentsFrench-language works237,207